AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2023
Feb 16, 2023
33148_dirs_2023-02-16_445c8cc9-b6e2-4229-aee4-bd7056e6c09f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2023-02-14
Reporting Person: Schwartz Jonathan David (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-14 | Stock Option (Right to Buy) | $20.04 | A | 124496 | Acquired | 2033-02-13 | Common Stock (124496) | Direct |
| 2023-02-14 | Restricted Stock Units | $ | A | 41541 | Acquired | Common Stock (41541) | Direct |
Footnotes
F1: This option represents a right to purchase a total of 124,496 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.